Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045489 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL8505283 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3681082 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3681089 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL30481166 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL22479710 | 0.88 | GRM8 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL11957999 | 0.88 | GRM8 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2483655 | 0.88 | BLM (0.55) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL16203683 | 0.88 | PTGS1 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2483653 | 0.88 | BLM (0.55) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115840050-B | Use of a reagent for detecting a metabolic marker in the preparation of a sleep disorder screening or diagnosis product | 四川大学 | 2024-12-20 | — | — | CN | claimed |
| CN-115840050-A | Application of reagent for detecting metabolic marker in preparation of sleep disorder screening or diagnosis product | 四川大学 | 2023-03-24 | — | — | CN | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| CN-120152627-A | Sweetness and/or flavor enhancer | 味之素株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-120152627-A | Sweetness and/or flavor enhancer | 味之素株式会社 | 2025-06-13 | — | — | CN | disclosed |
| EP-0693556-B1 | TRANSGLUTAMINASE ORIGINATING IN JAPANESE OYSTER | AJINOMOTO KK (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0885608-A1 | REMEDIES FOR BRAIN DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5736356-A | CULTIVATION OF TRANSFORMED CELL AS GELLING AGENT FOR GELATION OF PROTEIN SOLUTION OR SLURRY | AJINOMOTO CO., INC. (JP) | 1998-04-07 | — | — | US | disclosed |
| EP-0693556-A1 | TRANSGLUTAMINASE ORIGINATING IN JAPANESE OYSTER | Ajinomoto Co., Inc. (JP) | 1996-01-24 | — | — | EP | disclosed |
| WO-1992013530-A1 | TRANSGLUTAMINASE ENZYME INHIBITORS | MEDICIS CORPORATION (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1988007851-A1 | LIPOSOME ENTRAPPED N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | disclosed |
| US-4324743-A | Method of preparing gamma-L-glutamyl taurine | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | GRM8 3113/4885GRM6 3200/4885GRIN2D 3566/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | GRM8 4431/4885GRM6 3642/4885GRIN2D 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.